Indian biotech companies actively developing mRNA-based vaccines, therapeutics: DBT

IANS May 17, 2025 185 views

The Department of Biotechnology is championing India's emergence in mRNA therapeutic research through strategic policy initiatives. Innovative scientists are exploring groundbreaking vaccine and treatment technologies with potential global impact. Key experts are addressing challenges like product delivery and material sourcing while positioning India as a biotechnology leader. The BioE3 Policy aims to drive sustainable growth and accessible healthcare through cutting-edge scientific developments.

"mRNA-based therapies represent a groundbreaking advancement in biotechnology" - Dr. Varshneya Singh, DBT
New Delhi, May 17: The Indian biotech companies are actively developing mRNA-based vaccines and therapeutics, said a team of scientists at the Department of Biotechnology (DBT), under the Ministry of Science and Technology.

Key Points

1

Indian biotech companies lead mRNA therapeutic research

2

BioE3 Policy supports sustainable biomanufacturing innovations

3

Scientists highlight potential to tackle complex diseases

They were speaking at the 14th Webinar under the 'Webinar Series on Biofoundry and Biomanufacturing Initiative', along with Biotechnology Industry Research Assistance Council (BIRAC).

The session focused on "Biomanufacturing for mRNA Therapeutics", a vital component under the BioE3 (Biotechnology for Economy, Environment and Employment) Policy.

"The BioE3 Policy's vision is to foster high-performance biomanufacturing by supporting sustainable green growth. This approach marks a global shift toward sustainability, fuelling a 'BioRevolution' with the potential to reshape economies and societies," said Dr. Alka Sharma, Senior Adviser/Sc 'H', DBT.

She also informed that the 14th Webinar in this series focuses on mRNA therapeutics, a key thematic subsector under the policy.

"Several Indian biotech companies and research institutions are actively involved in developing mRNA-based vaccines and therapeutics," Sharma said, while also highlighting certain challenges plaguing the sector such as product delivery, product stability, and import dependence for raw materials.

Approved by the Union Cabinet and released by the Minister of Science and Technology, the BioE3 Policy aims to position India as a global leader in bio-based innovations.

It focuses on promoting sustainable biomanufacturing in diverse thematic areas including Precision Therapeutics such as mRNA therapeutics, supporting economic growth while promoting affordable healthcare accessible to the Indian population.

Dr. Varshneya Singh, Scientist 'D', DBT, provided an insightful overview of the mRNA therapeutics subsector.

"mRNA-based therapies represent a groundbreaking advancement in biotechnology, with the potential to tackle a broad spectrum of diseases, including cancer, genetic conditions, and infectious diseases," Singh said.

He provided a SWOT analysis of the subsector, identifying its strengths, weaknesses, opportunities, and threats.

Dr. Raghavan Varadarajan, IISc Bangalore explored cutting-edge advances in mRNA-LNP vaccine technology, emphasising its revolutionary role in modern medicine.

He talked about the mRNA vaccine design workflow; major advantages of mRNA vaccine modality; key structural elements of mRNA; workflow for LNP preparation, comparative analysis of different mRNA-LNP formulations, different kinds of microfluidic chips used, and comparison of different formulation methods.

The Webinar served as a collaborative forum, bringing together academia, industry experts, start-ups, and researchers to explore the latest developments and emerging opportunities in the field of mRNA therapeutics biomanufacturing.

Reader Comments

R
Rahul K.
This is fantastic news! After seeing how mRNA vaccines helped during COVID, it's great that India is investing in this technology. We need to be self-reliant in healthcare innovations. Hope this leads to affordable treatments for our population. 🇮🇳
P
Priya M.
While the initiative is commendable, I hope the government ensures proper funding and removes bureaucratic hurdles. Our scientists are brilliant but often face unnecessary delays in approvals and funding. Let's make 'Make in India' a reality in biotech too!
A
Arjun S.
mRNA technology could be a game-changer for diseases like cancer and genetic disorders. But we must address the 'import dependence for raw materials' issue mentioned. Atmanirbhar Bharat should mean complete self-reliance, not just final product manufacturing.
S
Sneha T.
As someone from biotech field, I'm excited but cautious. mRNA vaccines need ultra-cold storage - how will this work in rural India where electricity is unreliable? Research should focus on making these technologies practical for our ground realities.
V
Vikram J.
Great to see IISc Bangalore involved! Our IITs and research institutions have world-class talent. With proper government support and private partnerships, India can definitely become a global biotech leader. The 'BioRevolution' term sounds exciting! 🔬
N
Neha P.
Hope this doesn't remain just another policy document. We've seen many great initiatives announced but implementation is key. The focus on sustainable green growth is particularly important - development shouldn't come at environment's cost.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Your email won't be published


Disclaimer: Comments here reflect the author's views alone. Insulting or using offensive language against individuals, communities, religion, or the nation is illegal.

Tags:
mRNA Vaccines Indian Biotechnology DBT Biomanufacturing Precision Therapeutics Healthcare Innovation